ReLIA RF820 Immunofluorescence Analyzer

Product Overview

The ReLIA RF820 is a high-throughput 10-channel immunofluorescence analyzer designed for automated point-of-care testing (POCT) in clinical laboratories, emergency departments, and central diagnostic facilities. Manufactured by ReLIA Biotechnologies Inc. under an ISO 13485 certified quality management system, the RF820 represents the advanced tier of ReLIA's immunofluorescence platform, upgrading from the 3-channel RF810 to support simultaneous multi-sample testing with 10 independent reaction channels. The analyzer features fully automatic testing workflows — including automatic sample processing, result uploading, and waste card disposal — eliminating manual intervention between tests and reducing operator error. A precision constant-temperature system maintained at 18.5 plus or minus 0.25 degrees Celsius insulates antigen-antibody reactions from ambient temperature fluctuations, ensuring repeatable quantitative results across varying laboratory environments. The RF820 supports whole blood, micro whole blood, serum, plasma, urine, and other body fluid sample types, and is fully compatible with hospital information systems (HIS) and laboratory information systems (LIS) for bidirectional data transmission. With a comprehensive test menu spanning cardiovascular and cerebrovascular biomarkers, renal injury markers, inflammatory markers, and other clinical assays, the RF820 delivers quantitative immunofluorescence results in 2 to 8 minutes per test, making it an ideal rapid diagnostic platform for high-volume clinical testing environments.

Key Features & Advantages

• 10 independent reaction channels: Unlike the 3-channel RF810, the RF820 integrates ten parallel independent testing channels, enabling simultaneous processing of multiple patient samples or different biomarker panels without sequential waiting. This dramatically increases daily testing throughput and random-access flexibility for high-volume clinical laboratories.
• Fully automatic intelligent workflow: Automatic test execution, automatic result upload to HIS/LIS, and automatic waste card disposal after each test eliminate manual handling between tests. Operators simply load the sample and insert the test card — the analyzer handles incubation, detection, data transmission, and waste management autonomously.
• Precision constant-temperature control at 18.5 plus or minus 0.25 degrees Celsius: A proprietary temperature regulation module maintains the reaction chamber at a tightly controlled 18.5 degrees Celsius, minimizing the impact of ambient high or low temperature variations on antigen-antibody reaction kinetics. This ensures consistent, repeatable, high-accuracy quantitative test data across all indoor working environments.
• Multiple sample type support: Compatible with whole blood, micro whole blood, serum, plasma, urine, and other body fluids. No mandatory sample dilution is required for whole blood specimens, eliminating hemolysis and dilution-induced result interference risks.
• Advanced fluorescein-streptavidin-biotin signal amplification: The RF820 adopts a direct fluorescein-labeled antibody detection principle combined with streptavidin-biotin dual amplification technology. This significantly elevates detection sensitivity, enabling trace-level biomarker quantification for early disease screening, and differs from traditional fluorescent microsphere platforms by simplifying the one-step reaction workflow.
• Bidirectional HIS/LIS integration: Full compatibility with hospital information systems and laboratory information systems enables automatic test data uploading, patient record archiving, result query, and batch report generation. This realizes standardized full-lifecycle digital data management for clinical labs.
• Rapid 2 to 8 minute turnaround time: Quantitative results are delivered within 2 to 8 minutes after test card insertion, supporting rapid clinical decision-making in emergency and critical care settings.
• Premium raw material sourcing: All core antibody and antigen raw materials for test cartridges are sourced from world-renowned U.S. suppliers, guaranteeing outstanding diagnostic specificity, ultra-high sensitivity, and stable batch-to-batch consistency across all test panels.
• QC program for precise results: Built-in quality control program supports continuous monitoring of analyzer performance and reagent lot consistency, ensuring reliable diagnostic accuracy over time.

Technical Specifications

• Model: ReLIA RF820 Immunofluorescence Analyzer
• Manufacturer: ReLIA Biotechnologies Inc. (R&D and production centers in Shenzhen and Jiangsu, China)
• Quality certification: ISO 13485 certified quality management system
• Channel design: 10 independent reaction channels for simultaneous multi-sample testing
• Detection principle: Direct fluorescein-labeled immunofluorescence chromatography with streptavidin-biotin signal amplification
• Constant temperature: 18.5 plus or minus 0.25 degrees Celsius reaction chamber temperature control
• Sample types: Whole blood, micro whole blood, serum, plasma, urine, and other body fluids
• Output time: Quantitative results in 2 to 8 minutes per test
• Workflow: Fully automatic — automatic testing, automatic result upload, automatic waste card disposal
• Data transmission: Bidirectional HIS/LIS compatible; supports automatic data upload, patient record archiving, result query, and batch report generation
• Quality control: Built-in QC program for continuous performance monitoring
• Raw materials: Core antibodies and antigens sourced from world-renowned U.S. suppliers
• Operation steps: (1) Add sample to test card; (2) Insert test card into channel; (3) Analyzer performs automatic incubation, detection, result output, and waste disposal

Comprehensive Test Menu

The RF820 supports the full ReLIA immunofluorescence test menu, covering the following biomarker panels:

• Cardiovascular & Cerebrovascular: S100-beta, ST2, HCY (homocysteine), GDF-15, cTnI/H-FABP (combined), cTnI/CK-MB/MYO (combined), cTnI/NT-proBNP (combined), NT-proBNP, BNP, hs-cTnI (high-sensitivity troponin I), cTnT, MYO (myoglobin), CK-MB, D-Dimer, H-FABP, Lp-PLA2, MPO, proBNP/D-Dimer (combined)
• Renal Injury: NGAL, Cys-C (cystatin C), beta-2-MG (beta-2 microglobulin), MAU (microalbumin), NGAL/MAU (combined)
• Inflammation: PCT (procalcitonin), Full-scale CRP, Micro-Blood PCT, SAA (serum amyloid A), IL-6 (interleukin-6), HBP (heparin-binding protein), PCT/IL-6 (combined), SAA/CRP (combined)
• Other Clinical Assays: AMH (anti-Mullerian hormone), beta-hCG, PROG (progesterone), G17 (gastrin-17), PG I/PG II (pepsinogen I/II), HbA1c (glycated hemoglobin), C-P/INS (C-peptide/insulin combined)

Comparison & Competitive Advantages

Compared to the ReLIA RF810 (3-channel immunofluorescence analyzer), the RF820 offers over 3x the testing throughput with 10 independent channels, making it the preferred choice for high-volume clinical laboratories and central diagnostic facilities where rapid multi-sample processing is critical. The RF820 adds fully automatic waste card disposal and intelligent workflow automation that the RF810 does not offer, further reducing operator workload and contamination risk. While the RF810 is ideal for emergency departments, remote medical stations, and resource-limited clinics with moderate testing volumes, the RF820 targets hospital central laboratories, reference labs, and large emergency departments requiring continuous high-throughput POCT operation. Both analyzers share the same precision constant-temperature system, fluorescein-streptavidin-biotin signal amplification technology, comprehensive biomarker test menu, and HIS/LIS interoperability, ensuring consistent diagnostic quality across the ReLIA platform. Compared to competing immunofluorescence analyzers from other manufacturers, the RF820 distinguishes itself through its 10-channel parallel processing capacity, fully automated waste disposal, premium U.S.-sourced raw materials, and the broadest test menu covering cardiovascular, renal, inflammatory, metabolic, and reproductive health biomarkers on a single platform.

Applications

The RF820 immunofluorescence analyzer is deployed across a wide range of clinical settings requiring rapid quantitative POCT diagnostics:

• Emergency departments: Rapid AMI (acute myocardial infarction) screening via cardiac troponin panels, sepsis screening via PCT/IL-6 combined testing, and stroke screening via S100-beta — all delivering results within minutes for time-critical clinical decisions.
• Central clinical laboratories: High-throughput multi-sample testing with 10 parallel channels supports large daily test volumes for routine cardiovascular, renal, inflammatory, and metabolic biomarker panels.
• ICU and CCU (intensive care and cardiac care units): Real-time disease monitoring and prognosis evaluation through serial biomarker testing, supporting dynamic patient status tracking and treatment response assessment.
• Community healthcare centers and clinics: Point-of-care diagnostic capability without sending samples to central labs, reducing turnaround time from hours to minutes.
• Nursing homes and health screening facilities: Convenient on-site testing for elderly and screening populations with minimal sample volume requirements.
• Pediatric departments: Micro-blood sample capability enables minimally invasive, child-friendly diagnostic testing.
• Veterinary and research laboratories: Multi-sample type and multi-biomarker flexibility supports diverse research and veterinary diagnostic applications.

Frequently Asked Questions

Q: What is the ReLIA RF820 immunofluorescence analyzer?

A: The RF820 is a 10-channel automated immunofluorescence analyzer for point-of-care testing (POCT), manufactured by ReLIA Biotechnologies Inc. It performs quantitative fluorescent immunoassay detection on whole blood, serum, plasma, urine, and other body fluid samples, delivering results in 2 to 8 minutes per test. It features fully automatic testing, result upload, and waste card disposal, with bidirectional HIS/LIS integration.

Q: What is the difference between the RF820 and RF810 immunofluorescence analyzers?

A: The primary difference is channel capacity: the RF820 has 10 independent reaction channels versus 3 channels on the RF810, providing over 3x testing throughput. The RF820 also adds fully automatic waste card disposal and intelligent workflow automation. Both share the same constant-temperature system, detection principle, test menu, and HIS/LIS compatibility. The RF820 is designed for high-volume laboratories, while the RF810 suits smaller clinics and emergency settings.

Q: What sample types does the RF820 support?

A: The RF820 supports whole blood, micro whole blood, serum, plasma, urine, and other body fluid samples. No mandatory sample dilution is required for whole blood specimens, which eliminates hemolysis and dilution-induced result interference risks.

Q: What biomarkers can the RF820 test?

A: The RF820 supports a comprehensive test menu including cardiovascular and cerebrovascular biomarkers (NT-proBNP, cTnI, hs-cTnI, CK-MB, MYO, D-Dimer, H-FABP, Lp-PLA2, MPO, S100-beta, ST2, HCY, GDF-15, BNP, cTnT, and combined panels), renal injury markers (NGAL, Cys-C, beta-2-MG, MAU, NGAL/MAU), inflammatory markers (PCT, CRP, SAA, IL-6, HBP, and combined panels), and other assays (AMH, beta-hCG, PROG, G17, PG I/PG II, HbA1c, C-P/INS).

Q: How long does it take to get results from the RF820?

A: The RF820 delivers quantitative test results in 2 to 8 minutes after test card insertion, depending on the specific biomarker assay being performed.

Q: Does the RF820 support HIS and LIS integration?

A: Yes, the RF820 is fully compatible with hospital information systems (HIS) and laboratory information systems (LIS). It supports bidirectional data transmission including automatic test result upload, patient record archiving, result query, and batch report generation.

Q: How does the RF820 maintain temperature control during testing?

A: The RF820 features a proprietary constant-temperature regulation module that maintains the reaction chamber at 18.5 plus or minus 0.25 degrees Celsius. This minimizes the impact of ambient temperature fluctuations on antigen-antibody reactions, ensuring consistent and repeatable quantitative results across varying laboratory environments.

Q: Is the RF820 ISO 13485 certified?

A: Yes, the RF820 is manufactured by ReLIA Biotechnologies Inc. under an ISO 13485 certified quality management system, with R&D and production centers in Shenzhen and Jiangsu, China. All core antibody and antigen raw materials are sourced from world-renowned U.S. suppliers to ensure diagnostic specificity and batch-to-batch consistency.